Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (AUTL) announced progress on its CAR T product candidate AUTO3 at the ASH Annual Meeting. The ALEXANDER study, focusing on relapsed/refractory diffuse large B cell lymphoma, showed AUTO3 to be well tolerated, with low rates of cytokine release syndrome and neurotoxicity. The overall objective response rate was 65%, with a complete response rate of 51%. Notably, higher dosing improved outcomes, with an 87% response rate at the highest dose. The company is evaluating a strategy to optimize AUTO3's development path and will provide updates in Q1 2021.
Autolus Therapeutics announced promising results from its AUTO1 CAR T cell therapy in the ongoing ALLCAR Phase 1 study for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). As of November 12, 2020, 20 patients had received AUTO1, showing a tolerance profile with no Grade 3 cytokine release syndrome. Among evaluable patients, 84% achieved minimal residual disease-negative complete response at one month, with encouraging overall survival rates. The pivotal Phase 1b/2 study is anticipated to enroll patients throughout 2021, with full data expected in 2022.
Autolus Therapeutics (AUTL) has announced promising results from a Phase 1 study of AUTO6, a GD2-targeting CAR T therapy. The study demonstrated rapid regression of solid tumors in children without causing neurotoxicity, a common side effect of similar therapies. All six patients in higher dosage cohorts displayed CAR T cell expansion and partial response. The company aims to enhance AUTO6's effectiveness with AUTO6NG, which is expected to enter clinical trials in 2021. The study underscores the potential of CAR T cells against advanced solid cancers, highlighting significant implications for neuroblastoma treatment.
Autolus Therapeutics (Nasdaq: AUTL) announced an upcoming investor conference call to discuss AUTO1 and AUTO3 data from the ASH Virtual Congress 2020. The call will feature Dr. Christian Itin, CEO, who will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:25 PM ET. Additionally, on December 7, 2020, the team will present their findings on CAR T cell therapies for adult Acute Lymphoblastic Leukemia and relapsed/refractory diffuse large B cell lymphoma. Webcasts of the events will be available on their website.
Autolus Therapeutics (AUTL) reported its Q3 2020 financial results, highlighting operational progress in clinical trials for AUTO3 and AUTO1 programs. The company presented promising data at the ESMO 2020, showing favorable outcomes for AUTO3 in DLBCL. As of September 30, 2020, cash and equivalents totaled $177.7 million, down from $212.0 million at June 30, 2020. Operating expenses increased to $42.7 million, with R&D expenses rising to $33.5 million from $27.3 million a year earlier. The net loss attributable to shareholders was $37.3 million, compared to $27.2 million in 2019.
Autolus Therapeutics plc (Nasdaq: AUTL) announced its upcoming third quarter 2020 financial results and operational highlights, which will be released before U.S. market opening on November 5, 2020. Management will conduct a conference call at 8:30 AM ET to discuss these results and provide a business update. Interested parties can access the webcast through the company's investor relations page. Details for accessing the call are also provided for both domestic and international callers, along with information for replay after the event.
Autolus Therapeutics (AUTL) announced significant progress on AUTO3, a dual-targeting CAR T cell therapy for diffuse large B cell lymphoma, during the ESMO Virtual Congress 2020. New data from the Phase 1/2 ALEXANDER study reveal a promising 64% complete response rate and a 71% overall response rate in evaluated patients. AUTO3 demonstrated a favorable safety profile, with low rates of neurotoxicity and no serious cytokine release syndrome reported. The results position AUTO3 as a potential best-in-class treatment option, highlighting its durability and efficacy in a patient cohort.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced an upcoming investor conference call to discuss data on its AUTO3 program presented at the ESMO Virtual Congress 2020. Key events include participation in the Wells Fargo Virtual Healthcare Conference on September 9, the H.C. Wainwright & Co conference on September 15, and the Cantor Fitzgerald conference on September 17. A detailed investor call regarding AUTO3 will occur on September 18, with Dr. Christian Itin and the clinical team. For additional details, visit Autolus.
Autolus Therapeutics (NASDAQ: AUTL) announced the initiation of its pivotal Phase 1b/2 AUTO1-AL1 study for adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). As of May 13, 2020, AUTO1 demonstrated a favorable safety profile, achieving an 84% MRD-negative complete response (CR) in 19 patients. Notably, event-free survival at 6 months was 62%, with overall survival at 72%. Meanwhile, progress on AUTO3 suggests potential use in outpatient settings. The company will discuss EHA data in a conference call on June 12, 2020.
Autolus Therapeutics plc (Nasdaq: AUTL) has rescheduled its investor conference call to discuss data from the European Hematology Association EHA25 Virtual Congress to June 12, 2020, at 7:30 am EDT. Previously set for June 15, the call will feature Dr. Christian Itin and the AUTO1 and AUTO3 clinical teams discussing CAR T cell therapies targeting adult Acute Lymphocytic Leukemia and relapsed/refractory Diffuse Large B Cell Lymphoma. Investors can join via a dial-in or webcast, with a replay available afterward.